BACKGROUND: Inflammation has a key role in the process of atherosclerosis. Production of leukotrienes by 5-lipoxygenase has been linked to atherosclerotic plaques and cardiovascular events. HYPOTHESIS: In this study, a selective 5-LO inhibitor will slow plaque progression using serial cardiac computed tomographic angiography (CCTA). METHODS:Patients with recent acute coronary syndrome (ACS) were prospectively assigned to one of 3 VIA-2291 doses (25 mg, 50 mg, 100 mg) or placebo by oral administration. All groups underwent CCTA at baseline and at 6 months' follow-up. Plaque types such as low-attenuation plaque (LAP), fibro-fatty tissue (FF), fibro-calcified plaque (FC), and dense calcium plaque (DC) were measured based upon predefined density threshold, and changes from baseline CCTA were analyzed. RESULTS: The final analysis included 54 patients (age, 56 ± 9 years; 85.1% male) with CCTA at baseline and 24 weeks. Evaluating on treatment VIA-2291 (all 3 doses, n = 37) demonstrated significant reductions in plaque progression compared with placebo (n = 17). VIA-2291 significantly reduced LAP (5.9 ± 20.7 mm3 vs -9.7 ± 33.3 mm3 ), FF (11.1 mm3 ± 13.3 mm3 vs -0.9 ± 2.7 mm3 ), and FC (-0.1 ± 6.22 mm3 vs -14.3 ± 6.2 mm3 ; all P < 0.05) and retarded the progression of DC (3.9 ± 3.2 mm3 vs 0.2 ± 0.4 mm3 ) compared with placebo. CONCLUSIONS:VIA-2291 resulted in slowed plaque progression compared with placebo across different plaque subtypes in patients with recent ACS (http://ClinicalTrials.gov NCT00358826).
RCT Entities:
BACKGROUND: Inflammation has a key role in the process of atherosclerosis. Production of leukotrienes by 5-lipoxygenase has been linked to atherosclerotic plaques and cardiovascular events. HYPOTHESIS: In this study, a selective 5-LO inhibitor will slow plaque progression using serial cardiac computed tomographic angiography (CCTA). METHODS:Patients with recent acute coronary syndrome (ACS) were prospectively assigned to one of 3 VIA-2291 doses (25 mg, 50 mg, 100 mg) or placebo by oral administration. All groups underwent CCTA at baseline and at 6 months' follow-up. Plaque types such as low-attenuation plaque (LAP), fibro-fatty tissue (FF), fibro-calcified plaque (FC), and dense calcium plaque (DC) were measured based upon predefined density threshold, and changes from baseline CCTA were analyzed. RESULTS: The final analysis included 54 patients (age, 56 ± 9 years; 85.1% male) with CCTA at baseline and 24 weeks. Evaluating on treatment VIA-2291 (all 3 doses, n = 37) demonstrated significant reductions in plaque progression compared with placebo (n = 17). VIA-2291 significantly reduced LAP (5.9 ± 20.7 mm3 vs -9.7 ± 33.3 mm3 ), FF (11.1 mm3 ± 13.3 mm3 vs -0.9 ± 2.7 mm3 ), and FC (-0.1 ± 6.22 mm3 vs -14.3 ± 6.2 mm3 ; all P < 0.05) and retarded the progression of DC (3.9 ± 3.2 mm3 vs 0.2 ± 0.4 mm3 ) compared with placebo. CONCLUSIONS:VIA-2291 resulted in slowed plaque progression compared with placebo across different plaque subtypes in patients with recent ACS (http://ClinicalTrials.gov NCT00358826).
Authors: Gilbert L Raff; Aiden Abidov; Stephan Achenbach; Daniel S Berman; Lawrence M Boxt; Matthew J Budoff; Victor Cheng; Tony DeFrance; Jeffrey C Hellinger; Ronald P Karlsberg Journal: J Cardiovasc Comput Tomogr Date: 2009-01-29
Authors: Stella-Lida Papadopoulou; Lisan A Neefjes; Hector M Garcia-Garcia; Willem-Jan Flu; Alexia Rossi; Anoeshka S Dharampal; Pieter H Kitslaar; Nico R Mollet; Susan Veldhof; Koen Nieman; Gregg W Stone; Patrick W Serruys; Gabriel P Krestin; Pim J de Feyter Journal: JACC Cardiovasc Imaging Date: 2012-03
Authors: Stephen J Nicholls; Amy Hsu; Kathy Wolski; Bo Hu; Ozgur Bayturan; Andrea Lavoie; Kiyoko Uno; E Murat Tuzcu; Steven E Nissen Journal: J Am Coll Cardiol Date: 2010-05-25 Impact factor: 24.094
Authors: Gregg W Stone; Akiko Maehara; Alexandra J Lansky; Bernard de Bruyne; Ecaterina Cristea; Gary S Mintz; Roxana Mehran; John McPherson; Naim Farhat; Steven P Marso; Helen Parise; Barry Templin; Roseann White; Zhen Zhang; Patrick W Serruys Journal: N Engl J Med Date: 2011-01-20 Impact factor: 91.245
Authors: Irfan Zeb; Dong Li; Khurram Nasir; Jennifer Malpeso; Aisha Batool; Ferdinand Flores; Christopher Dailing; Ronald P Karlsberg; Matthew Budoff Journal: Atherosclerosis Date: 2013-08-29 Impact factor: 5.162
Authors: Suguru Matsumoto; Rine Nakanishi; Dong Li; Anas Alani; Panteha Rezaeian; Sach Prabhu; Jeby Abraham; Michael A Fahmy; Christopher Dailing; Ferdinand Flores; Sajad Hamal; Alexander Broersen; Pieter H Kitslaar; Matthew J Budoff Journal: J Nutr Date: 2016-01-13 Impact factor: 4.798
Authors: Juan Gaztanaga; Michael Farkouh; James H F Rudd; Tilmann M Brotz; David Rosenbaum; Venkatesh Mani; Todd C Kerwin; Rebecca Taub; Jean-Claude Tardif; Ahmed Tawakol; Zahi A Fayad Journal: Atherosclerosis Date: 2015-02-24 Impact factor: 5.162
Authors: Rine Nakanishi; Wendy S Post; Kazuhiro Osawa; Eranthi Jayawardena; Michael Kim; Nasim Sheidaee; Negin Nezarat; Sina Rahmani; Nicholas Kim; Nicolai Hathiramani; Shriraj Susarla; Frank Palella; Mallory Witt; Michael J Blaha; Todd T Brown; Lawrence Kingsley; Sabina A Haberlen; Christopher Dailing; Matthew J Budoff Journal: Coron Artery Dis Date: 2018-01 Impact factor: 1.439
Authors: Suguru Matsumoto; Reda Ibrahim; Jean C Grégoire; Philippe L L'Allier; Josephine Pressacco; Jean-Claude Tardif; Matthew J Budoff Journal: Clin Cardiol Date: 2016-11-24 Impact factor: 2.882
Authors: Matthew Budoff; J Brent Muhlestein; Viet T Le; Heidi T May; Sion Roy; John R Nelson Journal: Clin Cardiol Date: 2018-01-24 Impact factor: 2.882